A New Milestone in Hair Science: KX-826 Phase III Results

Key Message
Clinically Studied Performance

· Evaluated in a multicenter, randomized, double-blind study

· Study findings suggest visible improvements in hair appearance

· Consistent trends observed across study groups

Well-Tolerated Profile

· Generally well tolerated in clinical evaluations

· No serious safety concerns reported

· Designed for daily topical scalp use

Advanced Scalp Science

· A topical androgen receptor(AR) antagonist

· Supports a balanced scalp environment

· Helps maintain a healthy hair growth cycle

KOSHINÉ KX-826 Series

· Developed based on clinically studied core ingredient

· Designed for consistent daily use

· Supports fuller, healthier-looking hair over time

Offer

Get 2×2ml KX-826 trial samples on orders over $200

This offer is ongoing.

 

Phase III Clinical Study Highlights

Key Metrics	KX-826 (0.5%)	KX-826 (1%)	Control
Usage	Twice daily	Once daily / Twice daily	—
Study Duration	6 months	6 months	6 months
Hair Appearance	Noticeable improvement	Enhanced improvement	Minimal change
Scalp Coverage	Looks fuller over time	Improved density appearance	—
Compared to Control	Positive difference observed	Greater visible improvement	—
Tolerability	Well tolerated	Well tolerated	Well tolerated
Study Scope	Multi-center (CN & US)	Multi-center (CN & US)	Multi-center (CN & US)

Information Source：https://en.kintor.com.cn/news_details/22.html